![Ambaw Bellete](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ambaw Bellete
Président chez
OncoSTING LLC
Fortune : - $ au 31/05/2026
Profil
Ambaw Bellete is currently Chairman at OncoSTING LLC and Director at Axiom REACH Foundation.
Former roles include President & Chief Operating Officer at CG Oncology, Inc. (2023–2026), Chief Executive Officer at Lion Healthcare Strategies LLC (2021–2023), Head-US Cancer Commercial Operations at Photocure ASA, Trustee at BioNJ, Inc., President at MCS, Inc. (2012–2019), Chief Operating Officer at FerGene, Inc., and President at Photocure, Inc. (2012–2019).
Education includes undergraduate studies at Murray State University (Kentucky).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 15/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Ambaw Bellete
| Sociétés | Poste | Début |
|---|---|---|
OncoSTING LLC
 OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma. | Président | - |
Anciens postes connus de Ambaw Bellete
| Sociétés | Poste | Fin |
|---|---|---|
| CG ONCOLOGY, INC. | President | - |
Photocure, Inc.
 Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company | President | 01/08/2019 |
MCS, Inc.
 MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry | President | 01/07/2019 |
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | President | - |
Formation de Ambaw Bellete
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
10
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
MCS, Inc.
MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry | Technology Services |
Photocure ASA
 Photocure ASA Medical SpecialtiesHealth Technology Develops and sells pharmaceuticals and medical devices | Health Technology |
Murray State University (Kentucky)
 Murray State University (Kentucky) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
CG Oncology, Inc.
 CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Photocure, Inc.
Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company | Health Services |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
OncoSTING LLC
OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma. |
Choisissez Zonebourse 
